Nuvectis Pharma (NVCT) Competitors $6.04 +0.09 (+1.43%) As of 12:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NVCT vs. KROS, SIGA, SVRA, MGTX, ANAB, OPT, ORKA, ORGO, BCAX, and AQSTShould you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Keros Therapeutics (KROS), Siga Technologies (SIGA), Savara (SVRA), MeiraGTx (MGTX), AnaptysBio (ANAB), Opthea (OPT), Oruka Therapeutics (ORKA), Organogenesis (ORGO), Bicara Therapeutics (BCAX), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry. Nuvectis Pharma vs. Its Competitors Keros Therapeutics Siga Technologies Savara MeiraGTx AnaptysBio Opthea Oruka Therapeutics Organogenesis Bicara Therapeutics Aquestive Therapeutics Keros Therapeutics (NASDAQ:KROS) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership. Do insiders & institutionals hold more shares of KROS or NVCT? 71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 20.6% of Keros Therapeutics shares are owned by insiders. Comparatively, 30.5% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is KROS or NVCT more profitable? Keros Therapeutics has a net margin of 8.06% compared to Nuvectis Pharma's net margin of 0.00%. Keros Therapeutics' return on equity of 2.96% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Keros Therapeutics8.06% 2.96% 2.74% Nuvectis Pharma N/A -150.81%-94.84% Do analysts rate KROS or NVCT? Keros Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 88.63%. Nuvectis Pharma has a consensus price target of $15.33, suggesting a potential upside of 154.07%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Nuvectis Pharma is more favorable than Keros Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keros Therapeutics 0 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, KROS or NVCT? Keros Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of -0.27, meaning that its stock price is 127% less volatile than the S&P 500. Does the media refer more to KROS or NVCT? In the previous week, Keros Therapeutics and Keros Therapeutics both had 3 articles in the media. Keros Therapeutics' average media sentiment score of 0.73 beat Nuvectis Pharma's score of 0.64 indicating that Keros Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvectis Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, KROS or NVCT? Nuvectis Pharma has lower revenue, but higher earnings than Keros Therapeutics. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKeros Therapeutics$3.55M181.98-$187.35M$0.3151.30Nuvectis PharmaN/AN/A-$19M-$1.17-5.16 SummaryKeros Therapeutics beats Nuvectis Pharma on 9 of the 14 factors compared between the two stocks. Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCT vs. The Competition Export to ExcelMetricNuvectis PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$153.65M$3.09B$5.65B$10.31BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-5.1620.8376.2125.99Price / SalesN/A445.51560.97124.87Price / CashN/A44.6737.5461.24Price / Book12.079.5812.486.28Net Income-$19M-$52.73M$3.29B$270.94M7 Day Performance-3.75%1.96%0.54%-0.21%1 Month Performance-11.90%5.66%3.06%5.68%1 Year Performance-2.03%18.58%61.86%27.59% Nuvectis Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCTNuvectis Pharma2.8851 of 5 stars$6.04+1.4%$15.33+154.1%-3.9%$153.65MN/A-5.168News CoveragePositive NewsKROSKeros Therapeutics3.1355 of 5 stars$15.90+2.2%$30.00+88.7%-72.0%$631.98M$3.55M51.29100Positive NewsSIGASiga Technologies1.7741 of 5 stars$9.37+6.7%N/A+30.1%$628.70M$138.72M8.2940Positive NewsSVRASavara2.543 of 5 stars$3.49-1.1%$7.50+114.9%-16.4%$610.11MN/A-6.9820MGTXMeiraGTx4.3543 of 5 stars$8.09+7.0%$24.00+196.7%+103.7%$608.18M$33.28M-3.97300Positive NewsANABAnaptysBio2.1814 of 5 stars$21.40+2.7%$46.13+115.5%-31.8%$583.46M$91.28M-4.78100Positive NewsOPTOpthea0.4355 of 5 stars$3.41+7.2%$1.33-60.9%-17.2%$583.10M$30K0.008Positive NewsHigh Trading VolumeORKAOruka Therapeutics2.6347 of 5 stars$17.12+10.1%$42.00+145.4%-36.9%$582.36MN/A-6.09N/AORGOOrganogenesis3.9297 of 5 stars$4.72+3.1%$7.50+58.9%+69.0%$581.01M$482.04M-33.71950News CoveragePositive NewsAnalyst ForecastHigh Trading VolumeBCAXBicara Therapeutics2.1293 of 5 stars$10.75+3.0%$32.25+200.0%-59.3%$569.64MN/A-3.3932Positive NewsAQSTAquestive Therapeutics1.9594 of 5 stars$5.17-8.8%$10.29+98.9%+8.2%$565.43M$57.56M-7.39160Gap Up Related Companies and Tools Related Companies KROS Alternatives SIGA Alternatives SVRA Alternatives MGTX Alternatives ANAB Alternatives OPT Alternatives ORKA Alternatives ORGO Alternatives BCAX Alternatives AQST Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVCT) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredMagnificent 7 being replaced by the “Secret 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NVCT Stock Alerts